1. Academic Validation
  2. ARE-PROTACs Enable Co-degradation of an Nrf2-MafG Heterodimer

ARE-PROTACs Enable Co-degradation of an Nrf2-MafG Heterodimer

  • J Med Chem. 2023 Mar 9. doi: 10.1021/acs.jmedchem.2c01909.
Jianai Ji 1 Sinan Ma 1 Yuxuan Zhu 1 Jinglong Zhao 1 Yuanyuan Tong 1 Qidong You 1 2 Zhengyu Jiang 1 2
Affiliations

Affiliations

  • 1 Jiang Su Key Laboratory of Drug Design and Optimization and State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China.
  • 2 Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Abstract

Proteolysis-targeting chimera (PROTAC) technology has emerged as a potential strategy to degrade "undruggable" proteins in recent years. Nrf2, an aberrantly activated transcription factor in Cancer, is generally considered undruggable as lacking active sites or allosteric pockets. Here, we constructed the chimeric molecule C2, which consists of an Nrf2-binding element and a CRBN ligand, as a first-in-class Nrf2 degrader. Surprisingly, C2 was found to selectively degrade an Nrf2-MafG heterodimer simultaneously via the ubiquitin-proteasome system. C2 impeded Nrf2-ARE transcriptional activity significantly and improved the sensitivity of NSCLC cells to Ferroptosis and therapeutic drugs. The degradation character of ARE-PROTACs suggests that the PROTAC hijacking the transcription element of TFs could achieve co-degradation of the transcription complex.

Figures
Products